MARKET

GSGTF

GSGTF

Gensight Biologi
EXMKT
3.100
NaN%
Closed 09:30 10/23 EDT
OPEN
--
PREV CLOSE
3.100
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
3.100
52 WEEK LOW
3.100
MARKET CAP
727.01M
P/E (TTM)
-35.6732
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GSGTF last week (1012-1016)?
Weekly Report · 6d ago
GenSight Biologics Closes EUR 1 Million Capital Raise via Shares and Warrants
TipRanks · 10/16 17:37
Weekly Report: what happened at GSGTF last week (1005-1009)?
Weekly Report · 10/12 09:47
GenSight’s Optogenetic RP Trial Results Published in NEJM, Underscoring Vision-Restoration Potential
TipRanks · 10/08 07:09
GenSight Bolsters Cash with €1 Million Raise as It Prepares RECOVER Phase III Trial
TipRanks · 10/08 05:38
GenSight Biologics Warns on Going-Concern as Exceptional Access Cash Buoys Operations
TipRanks · 10/07 23:32
Weekly Report: what happened at GSGTF last week (0928-1002)?
Weekly Report · 10/05 09:47
GenSight Boosts Cash Through Early Access as LUMEVOQ Manufacturing Transfer Completes
TipRanks · 09/29 23:07
More
About GSGTF
Gensight Biologics SA is a France-based company. The Company focuses on the development and commercialization of gene therapies for retinal neurodegenerative diseases and selected central nervous system disorders. It operates as a clinical-stage biopharmaceutical business specializing in innovative gene therapy platforms designed to preserve or restore vision in patients affected by severe ophthalmic conditions. Its activities are centered on two core technology platforms: Mitochondrial Targeting Sequence (MTS), which is used to address diseases linked to mitochondrial dysfunction, and optogenetics, which is intended to restore light sensitivity in retinal cells. It develops therapeutic candidates for inherited and acquired retinal disorders, including products designed for single-administration treatment through intravitreal injection. It conducts research, clinical development, and related commercialization activities in ophthalmology and neurodegenerative disease applications.

Webull offers Gensight Biologics SA stock information, including EXMKT: GSGTF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GSGTF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GSGTF stock methods without spending real money on the virtual paper trading platform.